Histone deacetylase inhibitors in combinatorial anticancer therapy / / Shabir Ahmad Ganai |
Autore | Ganai Shabir Ahmad |
Edizione | [1st ed. 2020.] |
Pubbl/distr/stampa | Gateway East, Singapore : , : Springer, , [2020] |
Descrizione fisica | 1 online resource (XVII, 258 p. 27 illus., 13 illus. in color.) |
Disciplina | 572.865 |
Soggetto topico |
Gene expression
Medical genetics |
ISBN | 981-15-8179-7 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Chapter 1_Epigenetic modifying enzymes. -Chapter 2_Epigenetic modifying enzymes implicated in cancer. -Chapter 3_Classification of histone deacetylases (HDACs). -Chapter 4_Implications of 18 HDAC isoforms in therapeutically monotonous cancers. –Chapter 5_Possible Mechanisms of HDACs in Cancer development -- Chapter 6_Different strategies employed for circumventing cancer resistance (chemo and radio) and mitigating toxicity. -Chapter 7_Limitations of conventional therapeutic regimens in treating cancer. -Chapter 8_Overview of epidrugs with special emphasis on HDAC inhibitors (HDACi) -- Chapter 9_HDAC inhibitors as promising epidrugs for treating cancer. -Chapter 10_ HDAC inhibitors in anticancer monotherapy. -Chapter 11_Distinct groups of histone deacetylase inhibitors (HDACi) based on the structural distinction, HDACs targeted. -Chapter 12_Limited efficacy of HDAC inhibitor-based monotherapy. -Chapter 13_Resistance mechanisms generated by cancer cells against HDACi based monotherapy. -Chapter 14_ Toxicity issue of HDAC inhibitor based monotherapy. -Chapter 15_Combinatorial therapeutic strategies of HDACi. -Chapter 16_Designing Selective HDACi using computational and medicinal chemistry approach. -Chapter 17. Current therapeutic challenges and future directions. . |
Record Nr. | UNINA-9910426053703321 |
Ganai Shabir Ahmad | ||
Gateway East, Singapore : , : Springer, , [2020] | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Histone Deacetylase Inhibitors — Epidrugs for Neurological Disorders / / by Shabir Ahmad Ganai |
Autore | Ganai Shabir Ahmad |
Edizione | [1st ed. 2019.] |
Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2019 |
Descrizione fisica | 1 online resource (XVII, 93 p. 8 illus., 5 illus. in color.) |
Disciplina | 612.8 |
Soggetto topico |
Neurosciences
Pharmacology Genetics Proteins Posttranslational modification Pharmacology/Toxicology Genetics and Genomics Protein Science Posttranslational Modification |
ISBN | 981-13-8019-8 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Chapter 1. Role of Epigenetics in neurological diseases -- Chapter 2. Epigenetic enzymes and the drawbacks of conventional therapeutic regimens -- Chapter 3. Distinct classes of HDACs -- Chapter 4. HDAC implications in neurological diseases -- Chapter 5. HDAC inhibitors and their structurally distinct groups -- Chapter 6. HDAC inhibitors as novel therapeutic option against therapeutically challenging neurological disorders -- Chapter 7. Current Challenges with HDAC inhibitor based therapeutic intervention against neurological maladies -- Chapter 8. Escalating need of isoform selective inhibitors for enhanced therapeutic efficacy -- Chapter 9. Combinatorial therapeutic regimens using HDAC inhibitors in conjunction with conventional therapeutic agents -- Chapter 10. Future directions of epigenetic research in tackling neurological complications. |
Record Nr. | UNINA-9910350356103321 |
Ganai Shabir Ahmad | ||
Singapore : , : Springer Singapore : , : Imprint : Springer, , 2019 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|